GLSI - 1 Drug 1 Mission: What Should Investors Expect for Greenwich Life Sciences?
Texas-based biotech Greenwich Life Sciences (NASDAQ: GLSI) is currently developing immunotherapy for use against certain types of breast cancer. Founded in 2006, the company was actually 2020's top-performing IPO, appearing on the market at $5.75 in September and hitting a low of $3.26 in November before peaking at $72 in December, when news first broke regarding positive phase 2b results in breast cancer patients. Investors were ecstatic, but the boost didn't last . The stock ended up being shorted heavily until it stabilized and is currently at about $32.
What caused such a dramatic rise and fall, and is the stock's valuation appealing now?
Image Source: Getty Images.
For further details see:
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?